Phase 2 randomized double-blind placebo-controlled pharmacokinetic interaction study of cannabidiol with stiripentol or valproate in epilepsy

Phase 2, randomised, double-blind trial of cannabidiol, stiripentol and valproic acid in epilepsy and Dravet syndrome (4 arms), sponsored by GW Pharmaceuticals. Primary endpoint: Pharmacokinetic parameters of stiripentol or valproate with and without cannabidiol or placebo. Started Jan 2016; status: completed.